Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Hold” by Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given a consensus rating of “Hold” by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company.

A number of research analysts recently commented on the stock. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wolfe Research cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Zacks Research downgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS:ZLDPF opened at $49.28 on Monday. Zealand Pharma A/S has a 52 week low of $35.93 and a 52 week high of $83.12. The stock has a market capitalization of $3.53 billion, a P/E ratio of 8.17 and a beta of 0.88. The firm has a fifty day simple moving average of $46.90 and a two-hundred day simple moving average of $48.19. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.